APEPTICO - Innovation in peptide drugs

SOLNATIDE: Read the most exciting news related to the exploration of safety, tolerability and clinical efficacy of SOLNATIDE IMP in patients infected with the 2019 new Coronavirus (SARS-CoV-2)

After preparing the Horizon 2020 Grant and Consortium Agreements in record time due to the urgent situation caused by the Corona pandemic, we now have kicked-off the SOLNATIDE project.

The Scientific Coordinator and initiator of the project Prof. Dr. Bernhard Fischer is CEO of the Viennese biotechnology company APEPTICO Forschung und Entwicklung GmbH which is proprietary owner of the medicinal product Solnatide IMP.

As coordinator, RTDS is responsible for the overall project coordination, as well as project management and communication.

The SOLNATIDE project in a nutshell

Funding: €1.626 million
Funding: European Commission (EC) call “H2020-SC1-PHE-CORONAVIRUS-2020” (grant no. 101003595)Project start: April 1st 2020
Duration: 21 months

Consortium: 5 partners from Austria, Germany, Italy and Spain (in alphabetic order)

  • APEPTICO Forschung und Entwicklung GmbH, Austria. Scientific coordinator.
  • BCN Peptides SA, Spain.
  • Ludwig-Maximilians-University Munich (LMU) University Hospital, Germany.
  • OPIS SRL, Italy.
  • RTDS Association, Austria. RTDS Association is responsible for the overall project coordination, as well as project management and communication.

LINK: https://ec.europa.eu/info/sites/info/files/research_and_innovation/research_by_area/documents/ec_rtd_cv-projects.pdf

This project has received funding from the EC special H2020 program “Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic (call ID: SC1-PHE-CORONAVIRUS-2020)) under the grant no. 101003595.

Read more...


APEPTICO Forschung und Entwicklung GmbH has signed the
MANIFESTO FOR EU COVID-19 RESEARCH
to maximise the accessibility of research results in the fight against COVID-10.


 

APEPTICO’s global survey on incidence of ARDS and outcomes in hospitalized patients with COVID-19 has been published by Critical Care

Vienna, Austria, 24nd August, 2020: APEPTICO Forschung und Entwicklung GmbH today announced that its global survey on incidence of ARDS and outcomes in hospitalized patients with COVID-19 has been published by Critical Care.

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared just over 7 months ago in Wuhan, China. Early reports indicated that although some cases are asymptomatic, 20% of COVID-19 cases follow a severe course, necessitating hospitalization, with a quarter of hospitalized patients requiring intensive care unit (ICU) facilities. Later reports substantiated these data, although ICU admission rates, proportion of patients receiving invasive mechanical ventilation (IMV), and mortality rates differ considerably between studies.

Acute respiratory distress syndrome (ARDS) is a frequent and life-threatening complication in COVID-19. Patients with moderate-to severe ARDS require invasive mechanical ventilation (IMV) and have a poor prognosis.

APEPTICO’s global survey resulted that among hospitalized COVID-19 patients, approximately 1/3 (33%) develop ARDS, 1/4 (26%) require transfer to an ICU, 1/6 (16%) receive IMV, and 1/6 (16%) die. For COVID-19 patients transferred to an ICU, nearly 2/3 (63%) receive IMV and 3/4 (75%) have ARDS. The mortality rate of ICU COVID-19 patients is 40% and of those who receive IMV 59%; the mortality rate in COVID-19-associated ARDS is 45%, and the incidence of ARDS among non-survivors of COVID-19 is 90%, despite increasing use of anti-viral therapies.

This study received funding support from the European Commission (EC), Grant No. 101003595 and from the Austrian Research Promotion Agency (FFG), Grant No.880862.

 

Read more...


#EuropeansAgainstCovid19

Now more than ever, it’s crucial for people to feel that we are stronger together. The European Union and its member states are collectively mobilising over €3 trillion to help save lives, jobs, and businesses, by supporting the thousands of people working together to make a difference.

#EuropeansAgainstCovid19

It’s not in division that we move forward, it’s in togetherness: with the researchers, medical staff, scientists, teachers, friends, and neighbours
behind the scenes.
Discover European stories of solidarity and hope that encourage all of us to stand strong.

https://www.europarl.europa.eu/europeans-against-covid19/
https://www.facebook.com/epoesterreich
https://www.instagram.com/euparlament_at/

Read more...


Schritt für Schritt gegen COVID-19

Please see the video made by the European Commission for facebook:

https://www.facebook.com/epoesterreich/videos/2583720018535945/